Prevention and Management of Hormonal Crisis during Theragnosis with LU-DOTA-TATE in Neuroendocrine Tumors. A Systematic Review and Approach Proposal

Journal of Clinical Medicine

Martín López-de-la-Torre¹  Juan-Francisco Merino-Torres²  MariaIsabel del Olmo-García²  JoseM. Soriano³  MariaAngustias Muros⁴  Pilar Bello⁵  Marc Agudelo⁵ 

[1] Endocrinology and Nutrition Department, University Hospital Virgen de las Nieves, 18014 Granada, Spain;Endocrinology and Nutrition Department, University and Polytechnic Hospital La Fe, 46026 Valencia, Spain;Food & Health Lab, Institute of Materials Science, University of Valencia, 46980 Valencia, Spain;Nuclear Medicine Department, University Hospital Virgen de las Nieves, 18014 Granada, Spain;Nuclear Medicine Department, University and Polytechnic Hospital La Fe, 46026 Valencia, Spain;

关键词: neuroendocrine tumors;    peptide receptor radionuclide therapy;    177Lu-DOTA-TATE;    hormonal crisis;    carcinoid syndrome;    carcinoid crisis;   

DOI  :  10.3390/jcm9072203

来源: DOAJ

【 摘 要 】

Neuroendocrine tumors (NETs) frequently overexpress somatostatin receptors (SSTR) on their cell surface. The first-line pharmacological treatment for inoperable metastatic functioning well-differentiated NETs are somatostatin analogs. On second line, Lu-DOTA-TATE (¹⁷⁷Lu-DOTA⁰ Tyr ³ octreotate) has shown stabilization of the disease and an increase in progression free survival, as well as effectiveness in controlling symptoms and increasing quality of life. The management of functional NETs before and during LU-DOTA-TATE treatment is specially challenging, as several complications such as severe carcinoid and catecholamine crisis have been described. The aim of this review is to establish practical guidance for the management and prevention of the most common hormonal crises during radionuclide treatment with Lu-DOTA-TATE: carcinoid syndrome (CS) and catecholamine hypersecretion, as well as to provide a brief commentary on other infrequent metabolic complications. To establish a practical approach, a systematic review was performed. This systematic review was developed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and conducted using MEDLINE (accessed from PubMed), Google Scholar and ClinicalTrials.gov. Literature searches found 449 citations, and finally nine were considered for this systematic review.

【 授权许可】

Unknown